Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 May 20;29(15):2040-5.
doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study

Tanya B Dorff  1 , Thomas W Flaig, Catherine M Tangen, Maha H A Hussain, Gregory P Swanson, David P Wood Jr, Wael A Sakr, Nancy A Dawson, Naomi B Haas, E David Crawford, Nicholas J Vogelzang, Ian M Thompson, L Michael Glode
Affiliations
Randomized Controlled Trial

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study

Tanya B Dorff et al. J Clin Oncol. .

Abstract

Purpose: Men with high-risk features (extraprostatic extension or high Gleason grade) face a high risk of prostate cancer recurrence after radical prostatectomy. Clinical trials of adjuvant systemic therapy for such patients have been limited.

Patients and methods: The SWOG (Southwest Oncology Group) S9921 study randomly assigned 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy. ADT consisted of goserelin and bicalutamide for 2 years.

Results: Although the final primary treatment comparison results are not ready for publication, this article reports results in the ADT-alone control arm with a median follow-up of 4.4 years. For these 481 men, the estimated 5-year biochemical failure-free survival is 92.5% (95% CI, 90 to 95), and 5-year overall survival is 95.9% (95% CI, 93.9 to 97.9).

Conclusion: The results of this trial, taken in context, make a compelling argument for counseling all high-risk patients with prostate cancer about adjuvant ADT. This article discusses the challenges in the design and implementation of clinical trials to take the next step forward in adjuvant therapy for prostate cancer because of the excellent survival achieved with currently available therapies and highlights the need for better molecular markers to personalize care.

Trial registration: ClinicalTrials.gov NCT00004124.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Survival of patients in the chemical androgen deprivation (CAD) –alone arm of the SWOG (Southwest Oncology Group) S9921 study.
See this image and copyright information in PMC

Comment in

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
    1. Carver BS, Bianco FJ, Jr, Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176:564–568. - PubMed
    1. Petrovich Z, Lieskovsky G, Stein JP, et al. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int. 2002;89:604–611. - PubMed
    1. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol. 2004;172:910–914. - PubMed
    1. Nguyen CT, Reuther AM, Stephenson AJ, et al. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol. 2009;181:75–80. - PubMed

Publication types

MeSH terms

Associated data

Grants and funding